• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类药物依赖药物治疗相关死亡率:死因裁判记录的比较分析

Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.

作者信息

Gibson Amy E, Degenhardt Louisa J

机构信息

National Drug and Alcohol Research Centre, University of New South Wales, Australia.

出版信息

Drug Alcohol Rev. 2007 Jul;26(4):405-10. doi: 10.1080/09595230701373834.

DOI:10.1080/09595230701373834
PMID:17564876
Abstract

INTRODUCTION AND AIMS

The aim of this study was to compare the mortality associated with oral naltrexone, methadone and buprenorphine in opioid dependence treatment, employing a retrospective data analysis using coronial and prescription data.

DESIGN AND METHODS

The number of deaths were identified through national coronial data and number of treatment recipients were estimated from 2000 to 2003 prescriptions and restricted medications data. Mortality rates were expressed as deaths per number of treatment episodes and per person-years at high and low risk of fatal opioid overdose.

RESULTS

Thirty-two oral naltrexone, one buprenorphine and 282 methadone-related deaths were identified. Mortality rates in the highest risk period in deaths per 100 person-years were 22.1 (14.6 - 32.2) for oral naltrexone following treatment cessation and 3.0 (2.3 - 3.9) for methadone during treatment induction. Rates in the lowest risk period in deaths per 100 person-years were 1.0 (0.3 - 2.2) during oral naltrexone treatment and 0.34 (0.3 - 0.4) during post-induction methadone treatment. The relative risk of death for oral naltrexone subjects was 7.4 times (high-risk period, p < 0.0001) or 2.8 times (low-risk period, p = 0.055) that of methadone subjects.

DISCUSSION AND CONCLUSIONS

This is the first comparison of mortality associated with these three pharmacotherapies for opioid dependence. The risk of death related to oral naltrexone appears higher than that related to methadone treatment.

摘要

引言与目的

本研究旨在通过使用死因裁判和处方数据进行回顾性数据分析,比较阿片类药物依赖治疗中口服纳曲酮、美沙酮和丁丙诺啡相关的死亡率。

设计与方法

通过国家死因裁判数据确定死亡人数,并根据2000年至2003年的处方和受限药物数据估算治疗接受者人数。死亡率以每治疗疗程的死亡人数以及每100人年中阿片类药物致命过量高风险和低风险时的死亡人数表示。

结果

确定了32例口服纳曲酮相关死亡、1例丁丙诺啡相关死亡和282例美沙酮相关死亡。每100人年中,口服纳曲酮停药后最高风险期的死亡率为22.1(14.6 - 32.2),美沙酮诱导治疗期间为3.0(2.3 - 3.9)。每100人年中,口服纳曲酮治疗期间最低风险期的死亡率为1.0(0.3 - 2.2),美沙酮诱导治疗后为0.34(0.3 - 0.4)。口服纳曲酮治疗对象的相对死亡风险是美沙酮治疗对象的7.4倍(高风险期,p < 0.0001)或2.8倍(低风险期,p = 0.055)。

讨论与结论

这是首次对这三种阿片类药物依赖药物治疗相关死亡率进行比较。口服纳曲酮相关的死亡风险似乎高于美沙酮治疗相关的死亡风险。

相似文献

1
Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.阿片类药物依赖药物治疗相关死亡率:死因裁判记录的比较分析
Drug Alcohol Rev. 2007 Jul;26(4):405-10. doi: 10.1080/09595230701373834.
2
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).澳大利亚阿片类药物依赖药物治疗国家评估(NEPOD)中的严重不良事件。
Addiction. 2004 Apr;99(4):450-60. doi: 10.1111/j.1360-0443.2004.00654.x.
3
Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.比较初次进入美沙酮和丁丙诺啡治疗后患者的治疗保留率和死亡率。
Addiction. 2009 Jul;104(7):1193-200. doi: 10.1111/j.1360-0443.2009.02627.x.
4
Opioid-dependent error processing.阿片类药物依赖的错误处理。
J Opioid Manag. 2011 Nov-Dec;7(6):443-9.
5
Comparing overdose mortality associated with methadone and buprenorphine treatment.比较与美沙酮和丁丙诺啡治疗相关的过量用药死亡率。
Drug Alcohol Depend. 2009 Sep 1;104(1-2):73-7. doi: 10.1016/j.drugalcdep.2009.03.020. Epub 2009 May 13.
6
Favorable mortality profile of naltrexone implants for opiate addiction.纳曲酮植入物治疗阿片类药物成瘾的良好死亡率。
J Addict Dis. 2010 Jan;29(1):30-50. doi: 10.1080/10550880903435988.
7
Exposure to opioid maintenance treatment reduces long-term mortality.接受阿片类药物维持治疗可降低长期死亡率。
Addiction. 2008 Mar;103(3):462-8. doi: 10.1111/j.1360-0443.2007.02090.x. Epub 2008 Jan 8.
8
Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.植入式纳曲酮与舌下含服丁丙诺啡的对比治疗、死亡率相关因素及不良事件概况
J Subst Abuse Treat. 2009 Oct;37(3):256-65. doi: 10.1016/j.jsat.2009.03.008. Epub 2009 Apr 25.
9
Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.一项覆盖全州的阿片类药物药物治疗项目20年间参与者的死亡率:风险因素及挽救的生命
Drug Alcohol Depend. 2009 Nov 1;105(1-2):9-15. doi: 10.1016/j.drugalcdep.2009.05.021. Epub 2009 Jul 15.
10
Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.美沙酮和丁丙诺啡治疗期间校正QT间期延长的患病率及临床相关性:一项死亡率评估研究。
Addiction. 2009 Jun;104(6):993-9. doi: 10.1111/j.1360-0443.2009.02549.x. Epub 2009 Apr 9.

引用本文的文献

1
Demographic and Clinical Characteristics of 907 Cases with Naltrexone Intoxication; a 14-Year Cross-Sectional Study.907例纳曲酮中毒患者的人口统计学和临床特征;一项为期14年的横断面研究。
Arch Acad Emerg Med. 2022 May 1;10(1):e34. doi: 10.22037/aaem.v10i1.1554. eCollection 2022.
2
Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic.新兴的病毒和细菌感染:在阿片类药物流行的时代
Infect Dis Ther. 2020 Dec;9(4):737-755. doi: 10.1007/s40121-020-00335-0. Epub 2020 Sep 11.
3
Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study.
优化出狱和监狱环境中阿片类药物使用障碍药物的影响:一项微观模拟建模研究。
Int J Drug Policy. 2021 May;91:102841. doi: 10.1016/j.drugpo.2020.102841. Epub 2020 Jul 22.
4
Interventions for female drug-using offenders.针对女性吸毒罪犯的干预措施。
Cochrane Database Syst Rev. 2019 Dec 13;12(12):CD010910. doi: 10.1002/14651858.CD010910.pub3.
5
Potential uses of naltrexone in emergency department patients with opioid use disorder.纳曲酮在急诊阿片类药物使用障碍患者中的潜在用途。
Clin Toxicol (Phila). 2019 Sep;57(9):753-759. doi: 10.1080/15563650.2019.1583342. Epub 2019 Mar 4.
6
The neurobiology of addiction.成瘾的神经生物学。
Ann N Y Acad Sci. 2019 Sep;1451(1):5-28. doi: 10.1111/nyas.13989. Epub 2019 Jan 15.
7
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.不计其数:阿片类药物使用障碍者停止口服纳曲酮治疗后的身体和情感困扰。
Drug Alcohol Depend. 2018 Nov 1;192:264-270. doi: 10.1016/j.drugalcdep.2018.08.019. Epub 2018 Oct 4.
8
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.非致死性阿片类药物过量后治疗阿片类药物使用障碍的药物与死亡率的关系:一项队列研究。
Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. Epub 2018 Jun 19.
9
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.阿片类物质使用障碍医学管理中的拮抗剂:历史和现有治疗策略。
Am J Addict. 2018 Apr;27(3):177-187. doi: 10.1111/ajad.12711.
10
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.长效纳曲酮与丁丙诺啡-纳洛酮预防阿片类药物复发的比较效果(X:BOT):一项多中心、开放标签、随机对照试验。
Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14.